SCHEMBL7541985

SCHEMBL7541985

CC(C)Oc1c(-c2ccc(C#N)cc2)c(=O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ FNTA P49354 2/20 0.37
▸ FNTB P49356 2/20 0.37
▸ MMP2 P08253 3/20 0.37
▸ MMP3 P08254 3/20 0.37
▸ KIF11 P52732 1/20 0.36
▸ XDH P47989 1/20 0.35
▸ SCN2A Q99250 1/20 0.35
▸ SCN10A Q9Y5Y9 1/20 0.35
▸ GRIA1 P42261 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ GRIA3 P42263 1/20 0.35
▸ GRIA4 P48058 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ SLC11A2 P49281 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3942599 0.78 PTGS2 (0.37) ALDH1A1
SCHEMBL3943393 0.78 MAPT (0.46) ALDH1A1HPGD
SCHEMBL7536375 0.77 PTGS2 (0.44) ALDH1A1CA12CA1CA2CA9
SCHEMBL7535266 0.74 PTPN5 (0.40) KIF11
SCHEMBL105821 0.69 ALDH1A3 (0.47) MMP2MMP3ALDH1A1CYP2A6CA12
SCHEMBL7661235 0.68 MMP2 (0.43) IRAK4MMP2MMP3SCN2ASCN10A
SCHEMBL3509636 0.67 MMP3 (0.59) MMP3KIF11ALDH1A1CYP2A6CA12
SCHEMBL7534843 0.67 ABCC9 (0.54) FNTAFNTBMMP2MMP3KIF11
SCHEMBL3934774 0.66 HDAC4 (0.45) ALDH1A1CA1CA2CA9
SCHEMBL7925775 0.66 PTGS2 (0.42) IRAK4MMP2MMP3KIF11XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020177613-A1 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers AMERICAN HOME PRODUCTS CORPORATION (US) 2002-11-28 — — US disclosed
US-6465523-B1 TREATMENT OF SMOOTH MUSCLE CONTRACTION DISORDERS SUCH AS URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE AMERICAN HOME PRODUCTS 2002-10-15 — — US disclosed
US-6462059-B1 TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION; URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, AND CEREBRAL VASCULAR DISEASE AMERICAN HOME PRODUCTS 2002-10-08 — — US disclosed
US-6376555-B1 MUSCLE RELAXANTS AMERICAN HOME PRODUCTS CORPORATION 2002-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177613-A1 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers KCNN3, KCNJ2, KCNE1 IRAK4 3536/4885FNTA 4527/4885FNTB 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback